PubMed=11751535; DOI=10.1093/clinchem/48.1.25
Zammatteo N., Lockman L., Brasseur F., De Plaen E., Lurquin C., Lobert P.-E., Hamels S., Boon T., Remacle J.
DNA microarray to monitor the expression of MAGE-A genes.
Clin. Chem. 48:25-34(2002)

PubMed=15585611; DOI=10.1158/1078-0432.CCR-04-0072
Tykodi S.S., Warren E.H., Thompson J.A., Riddell S.R., Childs R.W., Otterud B.E., Leppert M.F., Storb R., Sandmaier B.M.
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Clin. Cancer Res. 10:7799-7811(2004)

PubMed=18698046; DOI=10.1158/1078-0432.CCR-08-0028; PMCID=PMC2693478
Tykodi S.S., Fujii N., Vigneron N., Lu S.M., Mito J.K., Miranda M.X., Chou J., Voong L.N., Thompson J.A., Sandmaier B.M., Cresswell P., van den Eynde B.J., Riddell S.R., Warren E.H.
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.
Clin. Cancer Res. 14:5260-5269(2008)

PubMed=22892449; DOI=10.1097/CJI.0b013e318261d630; PMCID=PMC3423552
Tykodi S.S., Satoh S., Deming J.D., Chou J., Harrop R., Warren E.H.
CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.
J. Immunother. 35:523-533(2012)